RealNews

DOR, Army to work on potential bioweapon vaccine

Miami-based DOR BioPharma said it and its academic development partner Thomas Jefferson University have entered a cooperative research and development agreement with the U.S. Army’s Medical Research Institute of Infectious Diseases. The biopharmaceutical company said it and the Philadelphia university’s agreement with USAMRIID is to advance the development of DOR’s mucosally delivered vaccine for botulinum toxin. The major goal, DOR said, is to develop a safe and effective botulinum toxin vaccine for mucosal – oral or nasal – delivery. The company described botulinum neurotoxin as the most poisonous natural toxin known. DOR said human exposure to botulinum toxin by ingestion or by inhalation results in disruption of peripheral nerve function – any part of the nervous system except the brain and spinal cord – and flaccid paralysis – paralysis in which affected muscles are limp, with little resistance to passive movement. Full Story

OODA Analyst

OODA Analyst

OODA is comprised of a unique team of international experts capable of providing advanced intelligence and analysis, strategy and planning support, risk and threat management, training, decision support, crisis response, and security services to global corporations and governments.